LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

LLY

1,048.16

-1.32%↓

JNJ

209.3

-2.59%↓

ABBV

223.55

-1.56%↓

UNH

333.42

-2%↓

AZN

91.51

-0.11%↓

Home・Aandelen Lijst・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Open

SectorGezondheidszorg

112.58 0.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

111.12

Max

114

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.3M -53M
Verkoop	2.8M 51M
EPS	-0.82
Winstmarge	-103.131
Werknemers	283
EBITDA	-7.6M -48M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+21.83% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-535M 7B
Vorige openingsprijs	112.54
Vorige sluitingsprijs	112.58

Nieuwssentiment

By Acuity

50%

165 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

60 / 65.58 Steun & Weerstand

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 dec 2025, 17:39 UTC

Belangrijke Marktbewegers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 dec 2025, 23:44 UTC

Marktinformatie

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 dec 2025, 22:19 UTC

Marktinformatie

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

15 dec 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 dec 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 dec 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

ServiceNow Completes Acquisition Of Moveworks >NOW

15 dec 2025, 21:00 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:36 UTC

Marktinformatie

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 dec 2025, 20:31 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 dec 2025, 20:27 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 dec 2025, 20:15 UTC

Marktinformatie

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 dec 2025, 19:22 UTC

Marktinformatie

Gold and Silver Gain to Start Week -- Market Talk

15 dec 2025, 18:37 UTC

Marktinformatie

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 dec 2025, 18:29 UTC

Marktinformatie

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 dec 2025, 17:58 UTC

Marktinformatie

Canada Housing Market In Search Of a Bottom -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 dec 2025, 17:36 UTC

Winsten

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 dec 2025, 17:30 UTC

Acquisities, Fusies, Overnames

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

21.83% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 137.08 USD 21.83%

Hoogste 167 USD

Laagste 110 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Rhythm Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60 / 65.58Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

165 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.